1. Pink Sheet
  2. >>Vaccines

Big Gaps In Vaccination Supplies Highlighted In Whistleblower Complaint; Will RAPID Partnership Save The Day?

 
• By Sarah Karlin-Smith

Ousted BARDA chief says HHS leaders ignored his warnings that the US lacks the necessary supplies of needles and syringes to administer a widespread COVID-19 vaccination campaign, and it could take the country two years to have enough supplies. A new public-private partnership announced in March is working to fill in those gaps. 

Close-up medical syringe with a vaccine.
HHS has a new public-private partnership that might help fill a big gap in vaccine syringe and needle supplies • Source: Shutterstock

The US lacks the necessary supplies of needles and syringes to administer a widespread COVID-19 vaccination campaign and it could take the country two years to have enough supplies, ousted Biomedical Advanced Research and Development Authority Director Rick Bright warned government officials this winter as the coronavirus crisis emerged, but those claims fell on deaf ears, Bright’s whistleblower complaint says.

The Health and Human Services Department did not respond to a request for comment on Bright’s allegations or to a request for information on what the government is doing to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

US FDA Punts On New COVID-19 Framework’s Impact On Fall Shots

 
• By Sarah Karlin-Smith

The FDA’s advisors split on whether to update COVID-19 vaccines for the fall. The agency refused to discuss the impact of the new vaccine framework on impact availability.

MAHA Commission Outlines Enhanced Research On Drug Safety In Children

 
• By Cathy Kelly

Research would include initiatives on reproducing industry-sponsored studies, postmarket surveillance, and studies of long-term neurodevelopmental and metabolic outcomes for commonly prescribed pediatric drugs.

Legal, Process Problems May Plague New US FDA COVID-19 Vaccine Policy

 
• By Sarah Karlin-Smith

The FDA may have violated laws and regulations along with many norms in how it released its planned changes for COVID-19 vaccine approvals.

Observational, Retrospective Trials Could Retest Vaccines, HHS’ Kennedy Says

 
• By Derrick Gingery

The Health and Human Services secretary told a Senate appropriations subcommittee that placebo-controlled trials may not be necessary to ensure vaccine safety as the FDA released a framework requiring them for COVID-19 vaccines.

More from Pink Sheet

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.

Quotable: Top Experts On Policy Hot Topics

 
• By Anabel Costa-Ferreira

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.